0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Original Investigation |

Reduction of Inappropriate Benzodiazepine Prescriptions Among Older Adults Through Direct Patient Education:  The EMPOWER Cluster Randomized Trial

Cara Tannenbaum, MD, MSc1,2; Philippe Martin, BSc2; Robyn Tamblyn, PhD3,4; Andrea Benedetti, PhD3,5; Sara Ahmed, PhD6
[+] Author Affiliations
1Faculty of Medicine, Université de Montréal, Montréal, Quebec, Canada
2Faculty of Pharmacy, Université de Montréal, Montréal, Quebec, Canada
3Department of Medicine, McGill University, Montréal, Quebec, Canada
4Department of Epidemiology, Biostatistics, and Occupational Health, McGill University, Montréal, Quebec, Canada
5The Respiratory Epidemiology and Clinical Research Unit, McGill University Health Centre, Montréal, Quebec, Canada
6Faculty of Medicine, School of Physical & Occupational Therapy, McGill University, Montréal, Quebec, Canada
JAMA Intern Med. 2014;174(6):890-898. doi:10.1001/jamainternmed.2014.949.
Text Size: A A A
Published online

Importance  The American Board of Internal Medicine Foundation Choosing Wisely Campaign recommends against the use of benzodiazepine drugs for adults 65 years and older. The effect of direct patient education to catalyze collaborative care for reducing inappropriate prescriptions remains unknown.

Objective  To compare the effect of a direct-to-consumer educational intervention against usual care on benzodiazepine therapy discontinuation in community-dwelling older adults.

Design, Setting, and Participants  Cluster randomized trial (EMPOWER [Eliminating Medications Through Patient Ownership of End Results] study [2010-2012, 6-month follow-up]). Community pharmacies were randomly allocated to the intervention or control arm in nonstratified, blocked groups of 4. Participants (303 long-term users of benzodiazepine medication aged 65-95 years, recruited from 30 community pharmacies) were screened and enrolled prior to randomization: 15 pharmacies randomized to the educational intervention included 148 participants and 15 pharmacies randomized to the “wait list” control included 155 participants. Participants, physicians, pharmacists, and evaluators were blinded to outcome assessment.

Interventions  The active arm received a deprescribing patient empowerment intervention describing the risks of benzodiazepine use and a stepwise tapering protocol. The control arm received usual care.

Main Outcomes and Measures  Benzodiazepine therapy discontinuation at 6 months after randomization, ascertained by pharmacy medication renewal profiles.

Results  A total of 261 participants (86%) completed the 6-month follow-up. Of the recipients in the intervention group, 62% initiated conversation about benzodiazepine therapy cessation with a physician and/or pharmacist. At 6 months, 27% of the intervention group had discontinued benzodiazepine use compared with 5% of the control group (risk difference, 23% [95% CI, 14%-32%]; intracluster correlation, 0.008; number needed to treat, 4). Dose reduction occurred in an additional 11% (95% CI, 6%-16%). In multivariate subanalyses, age greater than 80 years, sex, duration of use, indication for use, dose, previous attempt to taper, and concomitant polypharmacy (10 drugs or more per day) did not have a significant interaction effect with benzodiazepine therapy discontinuation.

Conclusions and Relevance  Direct-to-consumer education effectively elicits shared decision making around the overuse of medications that increase the risk of harm in older adults.

Trial Registration  clinicaltrials.gov Identifier: NCT01148186

Figures in this Article

Sign in

Create a free personal account to sign up for alerts, share articles, and more.

Purchase Options

• Buy this article
• Subscribe to the journal

Figures

Place holder to copy figure label and caption
Figure 1.
Trial Flow
Graphic Jump Location
Place holder to copy figure label and caption
Figure 2.
Risk Differences for Discontinuation of Benzodiazepines in Subgroups

Forest plot of risk differences (95% CIs) for benzodiazepine discontinuation due to the intervention within subgroups of interest. ICC indicates intracluster correlation.

Graphic Jump Location

Tables

References

Correspondence

CME


You need to register in order to view this quiz.
Submit a Comment

Multimedia

Some tools below are only available to our subscribers or users with an online account.

Sign in

Create a free personal account to sign up for alerts, share articles, and more.

Purchase Options

• Buy this article
• Subscribe to the journal

Related Content

Customize your page view by dragging & repositioning the boxes below.

Articles Related By Topic
Related Collections
PubMed Articles
Jobs
brightcove.createExperiences();